SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing a sharp rebound, driven by renewed analyst confidence in robust AI server CPU demand and strategic leadership additions sparking major partnership speculation. While some in the community eye this as a significant buying opportunity, others remain wary of a 'dead cat bounce' following its post-earnings volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc is trending after its CFO and General Counsel abruptly departed amidst an ongoing SEC accounting probe, invalidated financial disclosures, and significantly lowered guidance, triggering a massive stock sell-off. While many in the community express serious concerns about the company's financial integrity and long-term outlook, others view the steep decline as an overreaction and a potential opportunity for a bounce.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio Inc. is trending after the FDA issued a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, raising concerns about trial design and following a clinical hold on a related program due to a patient tumor; community discussion is split between fears of significant setbacks and a belief that other key pipeline assets, like the AbbVie partnership, still offer substantial value.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is seeing heated debate leading into its Q4 earnings report, as bullish analysts and the rollout of new AI-powered features and price hikes contend with investor concerns over its valuation and a recent music catalog leak.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending after its NASDAQ debut was swiftly followed by a significant equity raise and reverse stock split, sparking a fierce debate among investors over immediate dilution versus the long-term funding for its potentially "revolutionary" muscle regeneration drug for Duchenne Muscular Dystrophy.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following news of Apollo Global Management's $3.4 billion loan for xAI to acquire its chips, reinforcing the massive, multi-year AI infrastructure buildout that has the community highly anticipating upcoming earnings amidst strong bullish sentiment.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following mixed earnings results that highlighted profitability alongside a revenue miss and cautious forward guidance, prompting community discussion around the stock's perceived deep undervaluation. Investors are actively debating whether the significant share price drop is an overreaction to management's prudent risk management strategy within a challenging fintech environment, with many seeing it as a buying opportunity for the AI-driven lending platform.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending ahead of its highly anticipated Q4 earnings report, with community sentiment sharply divided between expectations of a significant rally driven by potential profitability and AI lending growth, and fears of further declines amidst recent fintech sector weakness. Many current holders express frustration over recent price action while looking for a short squeeze, contrasted by bears anticipating a post-earnings dip.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

The community is actively discussing Rocket Companies following its CEO's optimistic remarks about achieving multi-year highs in mortgage loan volume and gain-on-sale performance, leading to expectations of a significant re-rating as its integrated platform benefits from housing market normalization and industry consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why SciSparc Stock Is Gaining Today

SciSparc shares are surging after it moved to acquire MUSE endoscopy IP, broadening beyond neuroscience into GERD device commercialization.read more...

<ul class="summary-bullets"><li>The company said it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device.</li><li>The number of shares issued to Xylo would be 19.99% of the issued and outstanding share capital of SciSparc as of the closing date of the transaction, SciSparc said.&nbsp;</li><li>Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion instead of issuing shares, it added.</li></ul> SciSparc Ltd. (SPRC) on Wednesday said that its majority-owned unit, NeuroThera Labs Inc., signed a binding term sheet to acquire a treasury of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras from Xylo Technologies Ltd.Shares of the company jumped as much as 34% in the pre-market session at the time of writing.<h2 class="st-heading-2">About The Rights And Patents</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3195068/0/en/SciSparc-to-Acquire-Treasury-of-Patents-for-Innovative-Medical-Endoscopy-Systems.html">said</a> it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device designed for a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). According to SciSparc, the GERD device market is projected to reach $3.03 billion by 2030 from about $2.5 billion in 2024.In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. The number of shares issued would be 19.99% of SciSparc's issued and outstanding share capital as of the transaction's closing date, the company said.Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion, rather than issuing shares. However, this is subject to negotiation and the signing of definitive acquisition agreements, the company added.<h2 class="st-heading-2">What Does SciSparc Intend To Do?</h2>Xylo had entered a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019 for commercialization in Greater China.SciSparc now intends to replicate this model across territories such as North America, Europe and Latin America by pursuing exclusive partnerships with regional distributors to accelerate worldwide commercialization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.SPRC stock is down by 68% this year and by about 49% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 

Equity

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 


SciSparc (SPRC) announced on Monday that it has decided to terminate the proposed merger with AutoMax Motors.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161557/0/en/SciSparc-Ltd-Announces-Framework-Agreement-Regarding-Merger-with-AutoMax-Motors.html">announced</a> that the decision was mutual, and the merger agreement is null, effective immediately. The two companies also established clear repayment terms for SciSparc’s existing loans to AutoMax, totaling a principal amount of $6.25 million. The companies did not provide a reason for scrapping the proposed merger.SPRC shares traded 2% higher at the time of writing. Scisparc stated that AutoMax will repay $4.25 million in principal, with interest, in a single lump sum payment on Jan. 1, 2028, and another $2 million in principal, with interest, in monthly installments starting Nov. 20, 2025. All accrued interest will be paid at the outset, the company added.Late in August, the pharmaceutical company said that its shareholders approved its proposed merger with AutoMax, a parallel vehicle importer in Israel. The two companies entered into a definitive agreement in April 2024, under which SciSparc would acquire 100% of AutoMax’s share capital by way of a reverse merger between SciSparc Merger Sub, a wholly owned subsidiary of the company, and AutoMax, with AutoMax continuing as a wholly owned subsidiary of SciSparc. The proposed merger was aimed at diversifying SciSparc’s portfolio and capitalizing on the expanding electric vehicle market in Israel.SciSparc is currently focused on a portfolio based on cannabinoid pharmaceuticals. It is developing drugs for the treatment of Tourette Syndrome, Alzheimer’s disease, and Autistic Spectrum Disorders (ASD), among others.&nbsp;SPRC stock is down 37% this year but is up approximately 3% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SciSparc And AutoMax Motors Scrap Proposed Merger

The decision was mutual, and the merger agreement is null, effective immediately, SciSparc said.

SciSparc’s (SPRC) shares soared over 61% on Thursday after the company announced its plans to launch an initiative to advance 3D protein modeling using quantum computing technology.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156166/0/en/SciSparc-Resolves-to-Launch-Innovative-Quantum-Computing-Enabled-3D-Protein-Modeling-Initiative-to-Revolutionize-AI-Drug-Discovery.html">will</a> form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling to create new intellectual property. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, with the goal of targeting applications in drug discovery for neurological and rare diseases. SciSparc also said that it expects to incorporate a new wholly owned Israeli subsidiary, which will operate the initiative.The firm explained that knowing a protein’s three-dimensional structure is key to understanding how it interacts in the body and how to design effective drugs. Scientists typically use computers to predict the 3D structure. However, the process has its challenges, including the dynamic nature of proteins, which involves constantly shifting between different conformations, SciSparc said.Quantum computing may simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with potential drugs with much higher accuracy, the company said. The firm expressed optimism that this may pave the way for breakthroughs in structural biology and personalized medicine.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_12_19_35_PM_png_a67dccb366.webp" alt="SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="64"><figcaption>SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to hit $10 by the end of the day.<stembedurl>https://stocktwits.com/Proecadguy/message/629996574</stembedurl>Late last month, the company said that its shareholders approved its proposed merger with AutoMax Motors, a parallel vehicle importer in Israel. Following the closing of the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company’s share capital. However, the merger's closing is subject to approval by the Israeli court.SPRC stock is down approximately 19% this year and up about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SciSparc Stock Soared 61% Today – Here’s An Important Update

The company will establish a dedicated research team to integrate quantum computing algorithms into 3D protein modeling, aiming to create new intellectual property.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.6832
Prev Close	$0.684
Open	$0.6635
Dividend Yield	0.00%
50-Day Moving Average	$1.40
Beta	0.82
Avg. Volume	2.42M
PE Ratio	-0.03

52-Week High	$12.14
52-Week Low	$0.5838
Market Capitalization	$2.98M
EPS (Annual)	-$22.65
Price to Book	-0.47
Revenue Per Employee	$653,000.00
Enterprise Value/EBITDA	N/A

SPRC
Scisparc Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest SPRC News

SPRCScisparc Ltd